866-997-4948(US-Canada Toll Free)

Risperdal Consta Analysis and Forecasts from 2003 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 31 Pages



GlobalDatas pharmaceuticals report, Risperdal Consta Analysis and Forecasts from 2003 to 2020 provides Risperdal sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2003-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Risperdal Consta including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Risperdal Consta including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2003-2020 for Risperdal Consta in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Risperdal Consta 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.4 Approval Status of Risperdal Consta 14
6.5 Factors Affecting Sales of Risperdal Consta 14
6.5.1 Risperdal Consta Associated with Lower Risk of Hospitalization 14
6.5.2 Risperdal Consta (Long-acting injection (RLAI) 14
6.5.3 Treatment of Schizophrenia in Adults and Adolescents 14
6.5.4 Risperdal versus Risperdal Consta 15
6.6 Drug Evaluation 15
6.6.1 Drug Risk Benefit Score 15
6.6.2 Intensity of Competition 16
6.7 Sales Forecasts 16
6.7.1 Target Patient Pool of Risperdal Consta 16
6.7.2 Dosing 17
6.7.3 Market Penetration 17
6.7.4 Annual Cost of Therapy 17
6.7.5 Sales Projections of Risperdal Consta 19

7 Schizophrenia Market: Appendix 28
7.1 Market Definitions 28
7.2 Abbreviations 28
7.3 Research Methodology 28
7.4 Drug Sales Estimates Model 30
7.5 Contact Us 30
7.6 Disclaimer 31
7.7 Sources 31

List of Table


Table 1: 12-week, Double-blind, Randomized, Placebo Controlled Trial, Risperdal Consta 14
Table 2: Approval Status of Risperdal Consta 14
Table 3: Drug Risk Benefit Score of Risperdal Consta 15
Table 4: Efficacy Results 15
Table 5: Annual Cost of Therapy, 2011 18
Table 6: Risperdal Consta, Schizophrenia, Global, Estimated Sales ($m), 20032020 19
Table 7: Risperdal Consta, Schizophrenia, The US, Estimated Sales ($m), 20032020 20
Table 8: Risperdal Consta, Schizophrenia, The UK, Estimated Sales ($m), 20032020 21
Table 9: Risperdal Consta, Schizophrenia, France, Estimated Sales ($m), 20052020 22
Table 10: Risperdal Consta, Schizophrenia, Germany, Estimated Sales ($m), 20032020 23
Table 11: Risperdal Consta, Schizophrenia, Italy, Estimated Sales ($m), 20052020 24
Table 12: Risperdal Consta, Schizophrenia, Spain, Estimated Sales ($m), 20042020 25
Table 13: Risperdal Consta, Schizophrenia, Japan, Estimated Sales ($m), 20092020 26

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Target Patient Pool of Risperdal Consta 17
Figure 6: Risperdal Consta, Schizophrenia, Global, Estimated Sales ($m), 20032020 19
Figure 7: Risperdal Consta, Schizophrenia, The US, Estimated Sales ($m), 20032020 20
Figure 8: Risperdal Consta, Schizophrenia, The UK, Estimated Sales ($m), 20032020 21
Figure 9: Risperdal Consta, Schizophrenia, France, Estimated Sales ($m), 20052020 22
Figure 10: Risperdal Consta, Schizophrenia, Germany, Estimated Sales ($m), 20032020 23
Figure 11: Risperdal Consta, Schizophrenia, Italy, Estimated Sales ($m), 20052020 24
Figure 12: Risperdal Consta, Schizophrenia, Spain, Estimated Sales ($m), 20042020 25
Figure 13: Risperdal Consta, Schizophrenia, Japan, Estimated Sales ($m), 20092020 26
Figure 14: Risperdal Consta, Schizophrenia, Global, Sales Distribution by Country (%), 2020 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *